Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRzeta And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT

Trial Profile

Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRzeta And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Tisagenlecleucel-T (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 20 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
    • 01 Dec 2015 Status changed from completed to active, no longer recruiting as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top